Rigel Pharmaceuticals, Inc. (RIGL) Financial Statements
Rigel Pharmaceuticals, Inc. (RIGL) reported trailing twelve-month revenue of $276.8M (up 3.3% year on year) and net income of $321.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $79.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RIGLRigel Pharmaceuticals, Inc.Follow RIGL — free
—
Price chart with a free account
- Market cap
- 899.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.5 | 59.3 | 108.6 | 149.2 | 120.2 | 116.9 | 179.3 | 294.3 | 276.8 | |
| Gross profit | 44.2 | 58.4 | 107.7 | 148.2 | 118.5 | 109.8 | 160.6 | 274.7 | 252.9 | |
| Research & development | 46.9 | 52.9 | 60.1 | 65.2 | 60.3 | 24.5 | 23.4 | 33.3 | 43.7 | |
| Operating income | -72.7 | -69.1 | -29.0 | -12.5 | -55.6 | -20.5 | 24.2 | 125.5 | 87.1 | |
| Pre-tax income | -70.5 | — | — | -17.3 | -58.6 | -25.1 | 18.4 | 121.8 | 85.6 | |
| Income tax | 0.0 | — | — | 0.6 | — | 0.0 | 0.9 | -245.2 | -236.3 | |
| Net income | -70.5 | -66.9 | -29.7 | -17.9 | -58.6 | -25.1 | 17.5 | 367.0 | 321.9 | |
| Diluted EPS ($) | -0.44 | -0.40 | -0.18 | -0.11 | -3.44 | -1.44 | 0.99 | 19.48 | 16.45 | |
| Diluted shares (mn) | — | 167.4 | 168.8 | 170.5 | 17.0 | 17.4 | 17.7 | 18.8 | — |
USD millions · SEC XBRL
Rigel Pharmaceuticals, Inc. — questions
- What is Rigel Pharmaceuticals, Inc.'s revenue?
- $276.8M over the twelve months to 2026-06-30, up 3.3% year on year, from its 10-Q and 10-K filings.
- What is Rigel Pharmaceuticals, Inc.'s net income?
- $321.9M over the twelve months to 2026-06-30.
- What is Rigel Pharmaceuticals, Inc.'s free cash flow?
- $79.4M over the twelve months to 2026-06-30.
- What are Rigel Pharmaceuticals, Inc.'s diluted earnings per share?
- $16.45 over the twelve months to 2026-06-30.
Every figure on this page comes from Rigel Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.